
Language
Search
News
- Bruker Introduces Novel Fourier 300, a Compact, Easy-to-Use 300 MHz NMR
- Bruker Corporation Reports Record Financial Results for the Fourth Quarter and Full Year 2009
- Bruker Announces Over 100 Systems Orders Received in the Second Half of 2009 from Global Stimulus...
- Bruker Announces Framework Agreement for EPR e-scan™ Beer Analyzers to Enable New Levels of Quality...
- World’s First 1000 MHz NMR Spectrometer Now Offers New Research Capabilities to European...
Upcoming Events
Stroke
Cerebroprotective Drug Trials
Courtesy of M. Eis, M. Neumaier, U. Pschorn
Boehringer Ingelheim Pharma KG, Dept CNS Research, Ingelheim, Germany

- These data were acquired using a BioSpec 47/40
Rat brains at three time-points after an MCAO* insult, with (bottom row) and without (top row) cerebroprotective drug treatment. The compound reduces the growth of both lesion volume and its severity (note the very different lesion size at the outset).
*MCAO: Middle Cerebral Artery Occlusion
